Semaglutide, tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO) published in the journal Nature Medicine.

Read More

Source: Medical Xpress